$25.62
0.85% today
Nasdaq, Dec 27, 03:51 pm CET
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$25.40
-0.89 3.39% 1M
-1.18 4.44% 6M
-2.69 9.58% YTD
-1.84 6.75% 1Y
-14.73 36.71% 3Y
-19.10 42.92% 5Y
-19.10 42.92% 10Y
Nasdaq, Closing price Thu, Dec 26 2024
+0.17 0.67%
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Key metrics

Market capitalization $11.29b
Enterprise Value $21.28b
P/E (TTM) P/E ratio 9.94
EV/FCF (TTM) EV/FCF 7.54
EV/Sales (TTM) EV/Sales 9.39
P/S ratio (TTM) P/S ratio 4.98
P/B ratio (TTM) P/B ratio 1.65
Dividend yield 3.31%
Last dividend (FY24) $0.84
Revenue growth (TTM) Revenue growth -2.52%
Revenue (TTM) Revenue $2.27b
EBIT (operating result TTM) EBIT $1.54b
Free Cash Flow (TTM) Free Cash Flow $2.82b
Cash position $998.55m
EPS (TTM) EPS $2.56
P/E forward 16.49
P/S forward 4.30
EV/Sales forward 8.10
Short interest 3.67%
Show more

Is Royalty Pharma plc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy
91%
Hold
9%

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,266 2,266
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 720 720
41% 41%
32%
- Research and Development Expense 2.50 2.50
98% 98%
0%
1,544 1,544
53% 53%
68%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,544 1,544
53% 53%
68%
Net Profit 1,146 1,146
521% 521%
51%

In millions USD.

Don't miss a Thing! We will send you all news about Royalty Pharma plc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Positive
Finbold
2 days ago
As we enter the tail end of 2024, which has been a great year for the markets, as the S&P 500 has rallied by 27.35% since the beginning of the year, one question lies on the minds of investors the world over — what do I invest in for next year?
Positive
The Motley Fool
14 days ago
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally. Royalty Pharma (RPRX 0.04%), W.P.
Positive
The Motley Fool
23 days ago
The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A couple of overlooked dividend payers offer high yields and reliable dividend payout growth, but you wouldn't know it by looking at their stock prices.
More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office United Kingdom
CEO Pablo Legorreta
Employees 89
Founded 1996
Website royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today